Insider Transactions in Q2 2023 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Octavio Espinoza Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
375
+1.51%
|
$21,000
$56.78 P/Share
|
|
Jun 30
2023
|
Matthew E Korenberg President & COO |
BUY
Other acquisition or disposition
|
Direct |
376
+0.38%
|
$21,056
$56.78 P/Share
|
|
Jun 09
2023
|
Stephen L Sabba Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,142
+4.07%
|
-
|
|
Jun 09
2023
|
John W Kozarich Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,142
+2.8%
|
-
|
|
Jun 09
2023
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,142
+3.88%
|
-
|
|
Jun 09
2023
|
Nancy Ryan Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,142
+14.81%
|
-
|
|
Jun 09
2023
|
Todd C Davis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
420
-0.6%
|
$30,660
$73.76 P/Share
|
|
Jun 09
2023
|
Jason Haas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,142
+21.6%
|
-
|
|
Jun 09
2023
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,142
+1.57%
|
-
|
|
May 16
2023
|
John W Kozarich Director |
SELL
Open market or private sale
|
Direct |
4,444
-10.35%
|
$342,188
$77.2 P/Share
|
|
May 10
2023
|
Stephen L Sabba Director |
SELL
Open market or private sale
|
Direct |
6,408
-19.91%
|
$493,416
$77.13 P/Share
|
|
May 10
2023
|
Stephen L Sabba Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,408
+16.6%
|
-
|
|
May 08
2023
|
John W Kozarich Director |
SELL
Open market or private sale
|
Direct |
6,408
-6.67%
|
$487,008
$76.81 P/Share
|
|
May 08
2023
|
John W Kozarich Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,408
+11.64%
|
$115,344
$18.82 P/Share
|